According to the latest market research study by Technavio, the global protein therapeutics market is expected to grow at a CAGR of close to 8% during the forecast period of 2017 to 2021.
This report by Technavio provides an in-depth analysis of the global protein therapeutics market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Technavio research analysts categorize the market based on the product type
Source: Technavio
Click here to request a free sample of this report
The top three revenue contributing product segments are discussed below
Global mAbs market: An increased occurrence of cancer and benefits associated with next-generation antibodies are anticipated to fuel growth in the protein therapeutics market. Growing cancer incidences have increased the sales of mAbs such as BLINCYTO, Removab, GAZYVA, and POTELIGEO, which are the major next-generation antibodies used to treat cancer.
“Rising use of antibody-drug conjugates in drug development increases revenue generation in the global protein therapeutics market. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have proved to be powerful and efficient in treating diseases, including cancers and hematological malignancies,” says Sapna Jha, a lead analyst at Technavio for research on central nervous system.
Global human insulin market: The human insulin market is anticipated to witness high growth during the forecast period. Aspects such as the rising incidence of type 1 and type 2 diabetes, growth in the obese individuals, and the rise in older population will contribute to this growth.
Global EPO market: The global EPO market is growing slowly as many EPO drugs have either expired or are set to expire during the forecast period. These patent expiries lead to the entry of biosimilars in the market. The market presents a huge opportunity for the uptake of biosimilar EPO drugs because of the safety and efficiency concerns of biosimilars that leads to their noncompliance among individuals.
Ask an analyst to know more about this report
The top vendors operating in the global protein therapeutics market are:
- AbbVie
- Amgen
- F. Hoffmann-La Roche
- Johnson & Johnson
- Merck
- Novo Nordisk
The other prominent vendors in the market include Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, BioGenomics, Biopartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, MacroGenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, and XOMA.
A more detailed analysis is available in the Technavio report titled, ‘Global Protein Therapeutics Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports
- Global Chemotherapy-Induced Nausea and Vomiting Drugs Market 2017-2021
- Global Peptide Therapeutics Market 2016-2020
- Global Cystic Fibrosis Therapeutics Market 2016-2020
To read more press releases – click here
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
